Kinghorn G R, Abeywickreme I, Jeavons M, Rowland M, Barton I, Al-Hasani G, Potter C W, Hickmott E
Genitourin Med. 1986 Feb;62(1):33-7. doi: 10.1136/sti.62.1.33.
Forty patients presenting with first episode genital herpes were randomly allocated to seven day treatment with oral acyclovir alone, placebo alone, oral acyclovir plus co-trimoxazole, or placebo plus co-trimoxazole. Patients receiving acyclovir had significantly shorter periods of viral shedding (p less than 0.001), pain (p = 0.03), and times to lesion healing (p less than 0.05). Averaged over all patients there was no evidence that co-trimoxazole affected any of the variables, though in women cotrimoxazole was associated with a shorter time to lesion healing (p less than 0.01). Furthermore, the combination treatment gave significantly shorter times to lesion healing than acyclovir alone, placebo alone, or placebo and co-trimoxazole (p = 0.01) and good trends elsewhere (external lesions and duration of pain). Neither drug was associated with any adverse events or toxicity or influenced the subsequent recurrence rate.
40例初发性生殖器疱疹患者被随机分为四组,分别接受为期7天的单一口服阿昔洛韦治疗、单一安慰剂治疗、口服阿昔洛韦加复方新诺明治疗或安慰剂加复方新诺明治疗。接受阿昔洛韦治疗的患者病毒排出期(p<0.001)、疼痛期(p=0.03)和皮损愈合时间(p<0.05)均显著缩短。在所有患者中,没有证据表明复方新诺明会影响任何变量,不过在女性患者中,复方新诺明与较短的皮损愈合时间相关(p<0.01)。此外,联合治疗组的皮损愈合时间显著短于单一阿昔洛韦组、单一安慰剂组或安慰剂加复方新诺明组(p=0.01),在其他方面(外部皮损和疼痛持续时间)也有良好趋势。两种药物均未出现任何不良事件或毒性反应,也未影响后续复发率。